Aardvark Therapeutics
NASDAQ: AARDSan Diego, US · Founded 2017 · Delaware corporation · 33 employees on LinkedIn · 3 known investors
Aardvark Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule drugs that inhibit hunger to treat metabolic diseases. Its lead compound, ARD-101, is an oral investigational drug for hunger-associated rare diseases that activates bitter taste receptors in the gut to trigger satiety signals, with potential applications in hyperphagia and obesity.
Founders & leadership
Aardvark Therapeutics was founded in 2017 by Tien Lee.
TL
Tien LeeinFounder & Chief Executive Officer
ZH
Zachary HornbyNamed on SEC filing
JB
Jerel BanksNamed on SEC filing
HJ
Henry JiNamed on SEC filing
BS
Bob ShinNamed on SEC filing
Board
JC
Jeffrey ChiBoard director
Investors · 3
Reported raises · per SEC filings
Form D private placements$103.1M disclosed across 3 rounds · 2019–2024
▶$85MraisedMay 2024 · 31 investors · BiotechnologyRule 506(b)
▶$85MraisedMay 2024 · 31 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jeffrey ChiDirector
- Victor TongDirector
- Nelson SunExecutive Officer
- Tien-Li LeeExecutive Officer, Director
- Offering amount
- $85M
- Amount sold
- $85M
- Sales commissions
- $1.7M
- Placement agents
- Cantor Fitzgerald & Co.
- First sale
- May 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$9.1MraisedJun 2021 · 8 investors · BiotechnologyRule 506(b)
▶$9.1MraisedJun 2021 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Zachary HornbyDirector
- Jerel BanksDirector
- Tien-Li LeeExecutive Officer, Director
- Jeffrey ChiDirector
- Henry JiDirector
- Bob ShinDirector
- Offering amount
- $30M
- Amount sold
- $9.1M
- First sale
- May 2021
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$9MraisedMay 2019 · 12 investors · BiotechnologyRule 506(b)
▶$9MraisedMay 2019 · 12 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Bob ShinDirector
- Tien-Li LeeExecutive Officer, Director
- Jeffrey ChiDirector
- Offering amount
- $15M
- Amount sold
- $9M
- First sale
- May 2019
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlap
Robinhood15 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Seeking Alpha15 shared keywordsSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
Simply Wall St12 shared keywordsSimply Wall St is an investment platform that provides financial data visualization and analysis tools for individual investors. The platform serves long-term investors globally by simplifying complex market information into visual and narrative formats to make stock investing more accessible.
StockTwits11 shared keywordsStocktwits operates an online community platform where investors and traders share ideas, analysis, and trade discussions organized around stock tickers. The page presented is its community guidelines rather than a product description.
Companies competing with Aardvark Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
We Think Aardvark Therapeutics (NASDAQ:AARD) Needs To Drive Business Growth Carefully - Simply Wall St Newssimplywall.st · Aug 2026
Aardvark Reports $14.4 Million Q2 Net Loss as ARD-101 Hold Continues | Quiver Quantitativequiverquant.com · Aug 2026
Aardvark Therapeutics posts Q2 loss and details ARD-101 hold | AARD Quarterly Report (10-Q)stocktitan.net · Aug 2026Frequently asked questions
- What does Aardvark Therapeutics do?
- Aardvark Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule drugs that inhibit hunger to treat metabolic diseases. Its lead compound, ARD-101, is an oral investigational drug for hunger-associated rare diseases that activates bitter taste receptors in the gut to trigger satiety signals, with potential applications in hyperphagia and obesity.
- Who founded Aardvark Therapeutics?
- Aardvark Therapeutics was founded by Tien Lee in 2017.
- Who are Aardvark Therapeutics's investors?
- Aardvark Therapeutics's investors include Decheng Capital, Vickers Venture Partners, LG Technology Ventures.
- How much funding has Aardvark Therapeutics raised?
- Aardvark Therapeutics has disclosed $103.1M raised across 3 rounds.
- Where is Aardvark Therapeutics headquartered?
- Aardvark Therapeutics is headquartered in San Diego, US.